Shares of Gilead Sciences Inc. (NASDAQ:GILD) have received an average recommendation of “Buy” from the thirty analysts that are presently covering the firm. Ten investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $100.91.

Several equities research analysts have weighed in on the stock. Piper Jaffray Cos. decreased their price target on shares of Gilead Sciences from $114.00 to $108.00 and set an “overweight” rating for the company in a research note on Tuesday, July 26th. Royal Bank Of Canada decreased their price target on shares of Gilead Sciences from $120.00 to $105.00 and set an “outperform” rating for the company in a research note on Tuesday, July 26th. Robert W. Baird reaffirmed an “outperform” rating and issued a $122.00 price target (down from $135.00) on shares of Gilead Sciences in a research note on Tuesday, July 26th. Jefferies Group reissued a “hold” rating and set a $93.00 target price (down from $97.00) on shares of Gilead Sciences in a research report on Tuesday, July 26th. Finally, Credit Suisse Group AG reissued a “buy” rating and set a $115.00 target price (down from $120.00) on shares of Gilead Sciences in a research report on Tuesday, July 26th.

In other Gilead Sciences news, Director Kevin E. Lofton sold 3,500 shares of the stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total transaction of $286,895.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the sale, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Van Hulzen Asset Management LLC boosted its stake in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the last quarter. Gemmer Asset Management LLC boosted its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares in the last quarter. Joel Isaacson & Co. LLC boosted its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares in the last quarter. Roble Belko & Company Inc boosted its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares in the last quarter. 78.00% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences (NASDAQ:GILD) opened at 73.41 on Friday. Gilead Sciences has a 1-year low of $72.21 and a 1-year high of $111.11. The firm has a market capitalization of $96.88 billion, a P/E ratio of 6.44 and a beta of 1.10. The stock’s 50 day moving average is $77.59 and its 200-day moving average is $84.05.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. During the same period in the previous year, the firm posted $3.15 earnings per share. The business’s revenue was down 5.7% compared to the same quarter last year. Analysts forecast that Gilead Sciences will post $11.76 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.56%. Gilead Sciences’s payout ratio is currently 16.56%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.